Other potential biomarkers of breast cancer trastuzumab response are proteins GNAS2, GNA13, RAB10, and ITB1 (Figs. 3, 4, 5, 8, and 9) that we discovered via proteomics-based analysis (Fig. 3). This evidence concerns the gene RAB10 and breast carcinoma.